J Lipid Atheroscler.  2020 Jan;9(1):162-171. 10.12997/jla.2020.9.1.162.

Efficacy and Safety of High-Dose Atorvastatin in Moderate-to-High Cardiovascular Risk Postmenopausal Korean Women with Dyslipidemia

Affiliations
  • 1Department of Internal Medicine, Jeju National University Hospital, Jeju, Korea. okdom@jejunu.ac.kr
  • 2Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea.
  • 3Department of Internal Medicine, Eulji Hospital, Seoul, Korea.
  • 4Department of Medicine/Cardiology, Cheil General Hospital, Seoul, Korea. h2oshin@naver.com

Abstract


OBJECTIVE
Postmenopausal women show a more atherogenic lipid profile and elevated cardiovascular risk compared to premenopausal women. The aim of this study was to investigate the efficacy and safety of high-dose atorvastatin on the improvement of the blood lipid profile of postmenopausal women in Korea.
METHODS
This study is a prospective, open-label, single-arm clinical trial that was conducted in 3 teaching hospitals. Postmenopausal women with a moderate-to-high cardiovascular risk, according to guidelines from the Korean Society of Lipid & Atherosclerosis, were enrolled. Participants were administered 20 mg of atorvastatin daily for the first 8 weeks, and if the targeted low-density lipoprotein cholesterol (LDL-C) level was not achieved, the dose was increased to 40 mg for the second 8 weeks. The primary endpoint was percentage change of LDL-C from baseline after 16 weeks of drug administration.
RESULTS
Forty-four women were enrolled, 28 of whom (75.6%) had diabetes mellitus. By the end of treatment period (16 weeks) all patients had achieved LDL-C target levels, with 33 (94.2%) of the participants achieving it after only 8 weeks of administration. After 16 weeks, LDL-C decreased by 45.8±16.7% (p<0.001) from the baseline, and total cholesterol (33.2±10.9%; p<0.001), triglyceride (24.2±37.5%; p=0.001), and apolipoprotein B (34.9±15.6%; p<0.001) also significantly decreased. Blood glucose and liver enzyme levels slightly increased, but none of the participants developed serious adverse events that would cause them to prematurely withdraw from the clinical trial.
CONCLUSION
20 and 40 mg atorvastatin was effective and safe for treating dyslipidemia in postmenopausal Korean women with moderate-to-high cardiovascular risk.

Keyword

Postmenopause; Koreans; Dyslipidemia; Atorvastatin

MeSH Terms

Apolipoproteins
Asian Continental Ancestry Group
Atherosclerosis
Atorvastatin Calcium*
Blood Glucose
Cholesterol
Diabetes Mellitus
Dyslipidemias*
Female
Hospitals, Teaching
Humans
Korea
Lipoproteins
Liver
Postmenopause
Prospective Studies
Triglycerides
Apolipoproteins
Atorvastatin Calcium
Blood Glucose
Cholesterol
Lipoproteins

Figure

  • Fig. 1 Patient disposition. FA, full analysis; PP, per protocol.


Reference

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366:1267–1278.
Article
2. Poli A. Atorvastatin: pharmacological characteristics and lipid-lowering effects. Drugs. 2007; 67 Suppl 1:3–15.
3. Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med. 1998; 158:577–584.
Article
4. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998; 81:582–587.
Article
5. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006; 355:549–559.
Article
6. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350:1495–1504.
Article
7. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364:685–696.
Article
8. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361:1149–1158.
Article
9. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003; 326:1423.
Article
10. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019; 73:e285–e350.
11. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014; 63:2889–2934.
Article
12. Kobayashi T, Homma Y. Effects of low-dose pravastatin on plasma levels of lipids and apolipoproteins in Japanese type II hyperlipoproteinemic subjects with apolipoprotein E phenotype E3/2, E3/3, and E4/3. J Clin Pharmacol. 2001; 41:1055–1058.
Article
13. Kong SH, Koo BK, Moon MK. Efficacy of moderate intensity statins in the treatment of dyslipidemia in Korean patients with type 2 diabetes mellitus. Diabetes Metab J. 2017; 41:23–30.
Article
14. Kwon JE, Kim J, Hyun S, Won H, Shin SY, Lee KJ, et al. Cholesterol lowering effects of low-dose statins in Korean patients. J Lipid Atheroscler. 2014; 3:21–28.
Article
15. Matsuzawa Y, Kita T, Mabuchi H, Matsuzaki M, Nakaya N, Oikawa S, et al. Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients. Circ J. 2003; 67:287–294.
Article
16. Wu CC, Sy R, Tanphaichitr V, Hin AT, Suyono S, Lee YT. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study. J Formos Med Assoc. 2002; 101:478–487.
17. Arai H, Sasaki J, Teramoto T. Comment on the new guidelines in USA by the JAS guidelines committee. J Atheroscler Thromb. 2014; 21:79–81.
Article
18. McPherson R, Frohlich J, Fodor G, Genest J. Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol. 2006; 22:913–927.
Article
19. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med. 1989; 321:641–646.
Article
20. Wu ZY, Wu XK, Zhang YW. Relationship of menopausal status and sex hormones to serum lipids and blood pressure. Int J Epidemiol. 1990; 19:297–302.
Article
21. Bush TL. The epidemiology of cardiovascular disease in postmenopausal women. Ann N Y Acad Sci. 1990; 592:263–271.
Article
22. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J. 1987; 114:413–419.
Article
23. Davidson MH, Maki KC, Karp SK, Ingram KA. Management of hypercholesterolaemia in postmenopausal women. Drugs Aging. 2002; 19:169–178.
Article
24. Son JI, Chin SO, Woo JT. Treatment guidelines for dyslipidemia: summary of the expanded second version. J Lipid Atheroscler. 2012; 1:45–59.
Article
25. Koh JH, Shin JH, Kim HS, Tahk SJ, Choi BI, Kim D, et al. Efficacy and safety of atorvastatin in patients with hypercholesterolemia. Korean Circ J. 1999; 29:928–936.
Article
26. Park JS, Kim YJ, Choi JY, Kim YN, Hong TJ, Kim DS, et al. Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia. Korean J Intern Med. 2010; 25:27–35.
Article
27. Park SY, Lee MK, Lim SC. Comparative drug evaluation of atorvastatin versus rosuvastatin in pharmacotherapy of Korean patients with dyslipidemia. Biomol Ther (Seoul). 2008; 16:54–60.
Article
28. Semenkovich CF, Goldberg AC, Goldberg IJ. Disorders of lipid metabolism. In : Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, editors. Williams textbook of endocrinology. 13th ed. Philadelphia (PA): Saunders;2016. p. 1660–1700.
29. John SS, Park JH, Chung HJ, Son JC, Kim KM, Kim BT. The effect of atorvastatin on serum lipid levels among patients with hypercholesterolemia. J Korean Acad Fam Med. 2004; 25:46–51.
30. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359:2195–2207.
Article
31. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012; 380:565–571.
Article
32. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010; 375:735–742.
Article
33. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321:405–412.
Article
34. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016; 37:2999–3058.
Article
35. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Atorvastatin: safety and tolerability. Expert Opin Drug Saf. 2010; 9:667–674.
Article
Full Text Links
  • JLA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr